Literature DB >> 21627539

Harmonization of growth hormone measurements with different immunoassays by data adjustment.

Anne Müller1, Markus Scholz, Oliver Blankenstein, Gerhard Binder, Roland Pfäffle, Antje Körner, Wieland Kiess, Annegret Heider, Martin Bidlingmaier, Joachim Thiery, Jürgen Kratzsch.   

Abstract

BACKGROUND: The aim of our study was to evaluate the between-assay variability of commercially available immunoassays for the measurement of human growth hormone (hGH). In addition, we asked whether the comparability of the diagnosis of childhood onset growth hormone deficiency could be improved by adjusting hGH results by statistical methods, such as linear regression, conversion factors, and quantile transformation.
METHODS: In archived sera from 312 children and adolescents (age: 17 days-17 years) hGH values between 0.01 and 16.5 ng/mL were determined by using the following immunoassays: AutoDELFIA (PerkinElmer), BC-IRMA (Beckman-Coulter), ELISA (Mediagnost), IMMULITE 2000 (Siemens), iSYS (IDS), Liaison (DiaSorin), UniCel DxI 800 Access (BeckmanCoulter) and "In house"-RIA (Tübingen).
RESULTS: The assays differed in median hGH concentrations by as much as 5.44 ng/mL (Immulite), and as little as 2.67 ng/mL (BC-IRMA). The mean difference between assays ranged from 0.35 to 2.71 ng/mL, whereas several samples displayed differences up to 11.4 ng/mL. The best correlation (r=0.992) was found between AutoDELFIA and Liasion, the lowest (r=0.864) was between an in-house RIA and iSYS. The between-assay CV (mean ± SD) of values within the cut-off range was 24.3% ± 7.4%, resulting in an assay-dependent diagnosis of growth hormone deficiency (GHD) in more than 27% of patients. Yet, adjustment of this data by linear regression or a conversion factor reduced the CV below 14%, and the ratio of assay-dependent diagnoses below 8%. Using quantile transformation, the CV and ratio were reduced to 11.4% and <1%, respectively.
CONCLUSIONS: hGH measurements using different assays vary significantly. Linear regression, conversion factors, or particularly quantile transformation are useful tools to improve comparability in the diagnostic procedure for the confirmation of GHD in childhood and adolescence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21627539     DOI: 10.1515/CCLM.2011.201

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  11 in total

1.  Harmonisation of growth hormone assays in australasia.

Authors:  James Davidson
Journal:  Clin Biochem Rev       Date:  2012-08

2.  Effects of Growth Hormone Treatment on Lipid Profiles.

Authors:  Toshihide Kubo; Mahoko Furujo; Kyohei Takahashi; Yuki Hyodo; Hiroki Tsuchiya; Mariko Hattori; Shoko Fujinaga; Kenji Urayama
Journal:  Indian J Pediatr       Date:  2017-11-11       Impact factor: 1.967

3.  Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.

Authors:  Giuseppe Reimondo; Marta Bondanelli; Maria Rosaria Ambrosio; Franco Grimaldi; Barbara Zaggia; Maria Chiara Zatelli; Barbara Allasino; Federica Laino; Emiliano Aroasio; Angela Termine; Pierantonio Conton; Agostino Paoletta; Ernesto Demenis; Ettore Degli Uberti; Massimo Terzolo
Journal:  Endocrine       Date:  2013-06-21       Impact factor: 3.633

Review 4.  Diagnosis of growth hormone deficiency in childhood.

Authors:  Takara Stanley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-02       Impact factor: 3.243

Review 5.  Provocative growth hormone testing in children: how did we get here and where do we go now?

Authors:  Camilia Kamoun; Colin Patrick Hawkes; Adda Grimberg
Journal:  J Pediatr Endocrinol Metab       Date:  2021-04-12       Impact factor: 1.520

Review 6.  Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.

Authors:  Margaret C S Boguszewski; Cesar L Boguszewski; Wassim Chemaitilly; Laurie E Cohen; Judith Gebauer; Claire Higham; Andrew R Hoffman; Michel Polak; Kevin C J Yuen; Nathalie Alos; Zoltan Antal; Martin Bidlingmaier; Beverley M K Biller; George Brabant; Catherine S Y Choong; Stefano Cianfarani; Peter E Clayton; Regis Coutant; Adriane A Cardoso-Demartini; Alberto Fernandez; Adda Grimberg; Kolbeinn Guðmundsson; Jaime Guevara-Aguirre; Ken K Y Ho; Reiko Horikawa; Andrea M Isidori; Jens Otto Lunde Jørgensen; Peter Kamenicky; Niki Karavitaki; John J Kopchick; Maya Lodish; Xiaoping Luo; Ann I McCormack; Lillian Meacham; Shlomo Melmed; Sogol Mostoufi Moab; Hermann L Müller; Sebastian J C M M Neggers; Manoel H Aguiar Oliveira; Keiichi Ozono; Patricia A Pennisi; Vera Popovic; Sally Radovick; Lars Savendahl; Philippe Touraine; Hanneke M van Santen; Gudmundur Johannsson
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

7.  Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease.

Authors:  Elisa Verrua; Emanuele Ferrante; Marcello Filopanti; Elena Malchiodi; Elisa Sala; Claudia Giavoli; Maura Arosio; Andrea Gerardo Lania; Cristina Lucia Ronchi; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Int J Endocrinol       Date:  2014-12-21       Impact factor: 3.257

Review 8.  Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Leandro Kasuki; Mônica R Gadelha
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

9.  Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology.

Authors:  Jung Hee Kim; Hyun Wook Chae; Sang Ouk Chin; Cheol Ryong Ku; Kyeong Hye Park; Dong Jun Lim; Kwang Joon Kim; Jung Soo Lim; Gyuri Kim; Yun Mi Choi; Seong Hee Ahn; Min Ji Jeon; Yul Hwangbo; Ju Hee Lee; Bu Kyung Kim; Yong Jun Choi; Kyung Ae Lee; Seong-Su Moon; Hwa Young Ahn; Hoon Sung Choi; Sang Mo Hong; Dong Yeob Shin; Ji A Seo; Se Hwa Kim; Seungjoon Oh; Sung Hoon Yu; Byung Joon Kim; Choong Ho Shin; Sung-Woon Kim; Chong Hwa Kim; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

10.  Modified Clonidine Testing for Growth Hormone Stimulation Reveals α2-Adrenoreceptor Sub Sensitivity in Children with Idiopathic Growth Hormone Deficiency.

Authors:  Christian Willaschek; Sebastian Meint; Klaus Rager; Reiner Buchhorn
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.